Ascendis Pharma Presents Long-Term Data for Achondroplasia Drug at ISDS 2026
Event summary
- Ascendis Pharma will present Week 104 data from its pivotal ApproaCH Trial of TransCon CNP (navepegritide) at ISDS 2026 on August 28, 2026.
- The data shows durable improvements in height, lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning.
- TransCon CNP was approved by the FDA in February 2026 under the trade name YUVIWEL® for pediatric patients with achondroplasia.
- The European Medicines Agency is reviewing the Marketing Authorisation Application for YUVIWEL, with a decision expected in Q4 2026.
The big picture
Ascendis Pharma's presentation of long-term data for TransCon CNP at ISDS 2026 underscores the drug's potential to address unmet medical needs in achondroplasia, a rare genetic condition affecting over 250,000 people worldwide. The strategic significance lies in the drug's ability to provide durable improvements in growth and physical functioning, positioning Ascendis Pharma as a key player in the rare disease space. The upcoming regulatory decision in Europe will be a critical milestone in the company's commercial strategy.
What we're watching
- Regulatory Approval
- Whether the European Medicines Agency will approve YUVIWEL in Q4 2026, expanding market access for Ascendis Pharma.
- Clinical Efficacy
- How the long-term data from the ApproaCH Trial will impact the adoption of TransCon CNP in the achondroplasia community.
- Competitive Dynamics
- The pace at which Ascendis Pharma can establish YUVIWEL as a leading treatment option for achondroplasia.